Your browser doesn't support javascript.
loading
MSIMEP: Predicting microsatellite instability from microarray DNA methylation tumor profiles.
Santamarina-García, Martín; Brea-Iglesias, Jenifer; Bramsen, Jesper Bertram; Fuentes-Losada, Mar; Caneiro-Gómez, Francisco Javier; Vázquez-Bueno, José Ángel; Lázare-Iglesias, Héctor; Fernández-Díaz, Natalia; Sánchez-Rivadulla, Laura; Betancor, Yoel Z; Ferreiro-Pantín, Miriam; Conesa-Zamora, Pablo; Antúnez-López, José Ramón; Kawazu, Masahito; Esteller, Manel; Andersen, Claus Lindbjerg; Tubio, Jose M C; López-López, Rafael; Ruiz-Bañobre, Juan.
Afiliação
  • Santamarina-García M; Genomes and Disease, Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain.
  • Brea-Iglesias J; Genomes and Disease, Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain.
  • Bramsen JB; Translational Oncology Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Álvaro Cunqueiro Hospital, 36213 Vigo, Spain.
  • Fuentes-Losada M; Department of Molecular Medicine, Aarhus University Hospital, 8200 Aarhus, Denmark.
  • Caneiro-Gómez FJ; Department of Medical Oncology, University Clinical Hospital of Santiago de Compostela (SERGAS), University of Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain.
  • Vázquez-Bueno JÁ; Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain.
  • Lázare-Iglesias H; Department of Pathology, University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain.
  • Fernández-Díaz N; Department of Pathology, Complejo Hospitalario Universitario de Ferrol, 15405 Ferrol, Spain.
  • Sánchez-Rivadulla L; Department of Pathology, University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain.
  • Betancor YZ; Department of Medical Oncology, University Clinical Hospital of Santiago de Compostela (SERGAS), University of Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain.
  • Ferreiro-Pantín M; Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain.
  • Conesa-Zamora P; Department of Gynaecology and Obstetrics, Complejo Hospitalario Universitario de Ferrol, 15405 Ferrol, Spain.
  • Antúnez-López JR; Genomes and Disease, Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain.
  • Kawazu M; Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain.
  • Esteller M; Genomes and Disease, Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain.
  • Andersen CL; Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain.
  • Tubio JMC; Department of Clinical Analysis, Santa Lucía University Hospital, 30202 Cartagena, Spain.
  • López-López R; Department of Pathology, University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain.
  • Ruiz-Bañobre J; Chiba Cancer Center, Research Institute, 260-0801 Chiba, Japan.
iScience ; 26(3): 106127, 2023 Mar 17.
Article em En | MEDLINE | ID: mdl-36879816
ABSTRACT
Deficiency in DNA MMR activity results in tumors with a hypermutator phenotype, termed microsatellite instability (MSI). Beyond its utility in Lynch syndrome screening algorithms, today MSI has gained importance as predictive biomarker for various anti-PD-1 therapies across many different tumor types. Over the past years, many computational methods have emerged to infer MSI using either DNA- or RNA-based approaches. Considering this together with the fact that MSI-high tumors frequently exhibit a hypermethylated phenotype, herein we developed and validated MSIMEP, a computational tool for predicting MSI status from microarray DNA methylation tumor profiles of colorectal cancer samples. We demonstrated that MSIMEP optimized and reduced models have high performance in predicting MSI in different colorectal cancer cohorts. Moreover, we tested its consistency in other tumor types with high prevalence of MSI such as gastric and endometrial cancers. Finally, we demonstrated better performance of both MSIMEP models vis-à-vis a MLH1 promoter methylation-based one in colorectal cancer.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article